- Molecular NameAbacavir
- SynonymABC
- Weight286.339
- Drugbank_IDDB01048
- ACS_NO168146-84-7
- Show 2D model
- LogP (experiment)1.2
- LogP (predicted, AB/LogP v2.0)1.67
- pka5.01
- LogD (pH=7, predicted)1.67
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.21
- LogSw (predicted, AB/LogsW2.0)0.16
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors4
- No.of HBond Acceptors7
- No.of Rotatable Bonds4
- TPSA101.88
- StatusFDA approved
- AdministrationN/A
- PharmacologyNucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability83.0
- Protein binding50.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. It is metabolised by alcohol dehydrogenase to 5'-carboxylic acid and by glucuronyl transferase to 5'-glucuronide.
- Half life1.53 h
- ExcretionRenal (1.2% abacavir, 30% 5'-carboxylic acid metabolite, 36% 5'-glucuronide metabolite, 15% unidentified minor metabolites). Fecal (16%)
- Urinary ExcretionN/A
- CleranceIn adults: mean apparent clearance is 0.56 (single 1200 mg dose) to 1.94 (100 mg dose) L/h/kg. In children (2 to 5 years): 0.08 (8 mg/kg body weight dose) to 0.12 (4 mg/kg dose) L/h/kg, (6 to 13 years): 0.03 to 0.05 L/h/kg, respectively.
- ToxicityLife-threatening hypersensitivity reactions have been reported, as well as life-threatening lactic acidosis and severe hepatomegaly with steatosis. Some myocardial degeneration has been noticed in rats and mice
- LD50 (rat)N/A
- LD50 (mouse)N/A